Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan. (Q53836718)

20 May 2018

title

Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan. (English)

1 reference

20 May 2018

0 references

1

1 reference

20 May 2018

Koji Oba

20

1 reference

20 May 2018

author name string

Hideaki Shiraishi

2

1 reference

20 May 2018

Eishin Oki

3

1 reference

20 May 2018

Mika Ishige

4

1 reference

20 May 2018

Toshiyuki Fukao

5

1 reference

20 May 2018

Yusuke Hamada

6

1 reference

20 May 2018

Norio Sakai

7

1 reference

20 May 2018

Fumihiro Ochi

8

1 reference

20 May 2018

Asami Watanabe

9

1 reference

20 May 2018

Sanae Kawakami

10

1 reference

20 May 2018

Kazuyo Kuzume

11

1 reference

20 May 2018

Kenji Watanabe

12

1 reference

20 May 2018

Koji Sameshima

13

1 reference

20 May 2018

Kiyotaka Nakamagoe

14

1 reference

20 May 2018

Akira Tamaoka

15

1 reference

20 May 2018

Naoko Asahina

16

1 reference

20 May 2018

Saki Yokoshiki

17

1 reference

20 May 2018

Takashi Miyakoshi

18

1 reference

20 May 2018

Kota Ono

19

1 reference

20 May 2018

Toshiyuki Isoe

21

1 reference

20 May 2018

Hiroshi Hayashi

22

1 reference

20 May 2018

Seiji Yamaguchi

23

1 reference

20 May 2018

Norihiro Sato

24

1 reference

20 May 2018

publication date

22 February 2018

1 reference

20 May 2018

Molecular Genetics and Metabolism Reports

published in

1 reference

20 May 2018

volume

15

1 reference

20 May 2018

page(s)

55-63

1 reference

20 May 2018

Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

The Biochemistry and Physiology of Mitochondrial Fatty Acid β-Oxidation and Its Genetic Disorders

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Mitochondrial trifunctional protein deficiency in human cultured fibroblasts: effects of bezafibrate.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Rhabdomyolysis: review of the literature

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Pathophysiology of fatty acid oxidation disorders

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Fatty acid oxidation disorders: outcome and long-term prognosis

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Mitochondrial fatty-acid oxidation disorders

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Fatty acid oxidation disorders

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

The mechanisms of action of PPARs

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

SF-36 health survey update

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Efficacy of bezafibrate on fibroblasts of glutaric acidemia type II patients evaluated using an in vitro probe acylcarnitine assay.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

A case of very-long-chain acyl-coenzyme A dehydrogenase deficiency with novel compound heterozygous mutations.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Bezafibrate for an inborn mitochondrial beta-oxidation defect.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

A method for quantitative acylcarnitine profiling in human skin fibroblasts using unlabelled palmitic acid: diagnosis of fatty acid oxidation disorders and differentiation between biochemical phenotypes of MCAD deficiency

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5852296

Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay

29 September 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGMR.2018.02.003

No effect of bezafibrate in patients with CPTII and VLCAD deficiencies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGMR.2018.02.003

Validation of a French-language version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGMR.2018.02.003

Role of MB isoforms (isomers) in the early diagnosis of acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGMR.2018.02.003

10.1016/J.YMGMR.2018.02.003

7 January 2021

Identifiers

DOI

1 reference

20 May 2018

PMC publication ID

5852296

1 reference

20 May 2018

PubMed publication ID

29552494

1 reference

20 May 2018